Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sponsors’ Use Of Adaptive Designs Appears To Be Growing

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A Drug Information Association working group survey found 477 studies between Jan. 1, 2008 and Sept. 1, 2011 utilized some type of adaptive design.


Related Content

Roche Oncology Trials Designed For “Learning On The Go”
R&D Productivity Still Lags: Study Shows Success Rates May Have Been Overestimated
Antibacterial Trials Can Benefit From Futility Analysis, Genentech Tells FDA
Fulyzaq Review Shows FDA Adapting Smoothly To Adaptive Trial Design
Best Practices For Adaptive Trial Designs Continue To Evolve
Simulation Of Clinical Scenarios Important To Support Adaptive Trial Designs
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Time To Be Creative With Adaptive Trials May Be Non-Pivotal Portion


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts